M&A footprint Aquilo Partners has a track record of advising on more than $20 billion in M&A and partnering transactions, signaling a strong value proposition for clients considering strategic exits, partnerships, or scale through acquisitions.

Capital raising With over $8 billion raised in capital across life science transactions, there is a clear capability to support clients seeking private placements, new funding rounds, or strategic investor syndication.

Life science focus Specialization spans biotechnology, big pharma, specialty pharma, medical devices, research tools and diagnostics, presenting targeted cross-sell opportunities for firms at various stages of development seeking advisory or financing help.

Boutique agility Small team size indicates personalized senior-attorney level attention on transactions, which can be marketed as a differentiator to mid to late-stage life science companies valuing hands-on, senior-led deal processes.

Strategic network Maintaining top-tier relationships across the global life science industry suggests opportunities to connect clients with potential strategic buyers, licensors, or co-development partners to accelerate deal momentum.